On March 25, 2026, Long Chau Pharmacy Network and the British pharmaceutical giant AstraZeneca officially announced their partnership to launch a next-generation biologic therapy featuring Tezepelumab. This breakthrough allows severe asthma patients in Vietnam to access world-class medical technology directly through local retail channels.
Strategic highlights of the therapy and partnership:
-
Innovative Mechanism of Action: Tezepelumab targets thymic stromal lymphopoietin (TSLP), a key cytokine that initiates the inflammatory response in asthma. This therapy significantly reduces dangerous exacerbations and improves lung function across various severe asthma phenotypes.
-
Reducing Oral Steroid Dependency: Clinical studies demonstrate that this active ingredient helps patients lower their dosage of oral corticosteroids (OCS), thereby minimizing side effects from long-term high-dose use while maintaining optimal disease control.
-
Expanding Medical Accessibility: Leveraging a network of nearly 2,500 pharmacies across 34 provinces, Long Chau serves as the “first medical touchpoint,” enabling Vietnam’s 4 million asthma patients to access the treatment easily at optimized costs with professional pharmacist guidance.
-
Market Stabilization Commitment: Despite global supply chain fluctuations, Long Chau pledges to maintain stable medicine prices and continue its free delivery service via its app to alleviate the financial burden of treatment for the public.
This collaboration goes beyond a business deal; it is a dedicated effort to raise healthcare standards and reduce asthma-related mortality, which currently claims 3,000 to 4,000 lives annually in Vietnam.